Transforming lives before disease defines them.
Discover the System
To transform healthcare from reactive treatment to proactive preservation of healthspan.
To detect and preempt the earliest disease signatures, years before clinical onset.
To make precision health a human right, not a privilege of wealth or geography.
The Cytognosis Platform establishes the first Global Positioning System for Health. Just as geographic GPS requires a map of the terrain, satellites that locate the traveler, and a navigator that computes the route, Cytognosis integrates three core technologies that continuously map, track, and navigate individual health trajectories, intercepting disease years before symptoms emerge.
"You have been diagnosed with a major depressive episode. You need to be hospitalized immediately."
"Your proinflammatory cytokines IL-6 and TNF-α
are elevated and early markers of major depression are
emerging.
Consider increasing physical activity, such as
swimming, and adopting a Mediterranean-style diet to
restore your mental health trajectory."
Transforms diagnosis from discrete categorical labels into continuous, universally standard health coordinates. Cytoverse fuses single-cell multi-omics, population genomics, and functional phenotypic data into disentangled biological axes, placing each person at a precise, evolving position within a high-dimensional health landscape.
Delivers programmable, real-time biosensing that triangulates each person's coordinates on the Cytoverse map. Active-reset protein sensors achieve 95 Hz oscillation with full reset under 60 seconds, scaling the continuous glucose monitoring paradigm from a single molecule to dozens of biomarkers, with sub-minute temporal resolution.
Privacy-first edge AI that converts molecular coordinates into personalized, mechanistically grounded guidance. Cytonome runs entirely on-device at under 5 mW, delivering proactive navigation during the 2 to 5 year window when biological perturbations remain reversible, before any clinical threshold is crossed.
The platform is general; the first deployment is not. We anchor in neuropsychiatric disease because four conditions converge there with rare clarity: the underlying biology is ready, noninvasive sensing is mature, noninvasive intervention works once personalized, and our team holds deep scientific lineage in the field.
Continuous, transdiagnostic disease axes are now established in neuropsychiatric and neurodegenerative conditions. Our team built the first single-cell Alzheimer's atlas (Nature, 2019) and the largest multi-cohort schizophrenia atlas (Science, 2024). Independent work has since confirmed that shared genetic dimensions organize 14 psychiatric disorders into a five-factor structure spanning 66% of cross-disorder genetic variance (Grotzinger et al., Nature 2026).
Mental and brain states can be tracked continuously today through three complementary signals: validated wearables for autonomic and circadian state (Oura Ring 4: r = 0.99 vs. ECG resting heart rate, r = 0.88 HRV), consumer EEG and fNIRS hybrids for prefrontal activity (Muse S Athena), and on-device language models fine-tuned against validated clinical instruments (PHQ-9, GAD-7, PSS-10, PCL-5) that quantify mental-state trajectories from natural conversation.
Cognitive and behavioral therapy, precision-targeted TMS, and lifestyle interventions (diet, sleep, exercise) are already effective. Each becomes substantially more effective when targeted to individual coordinates: continuous glucose monitoring already proved that identical meals produce dramatically different metabolic responses across people (Zeevi et al., Cell 2015), and the same logic applies to brain stimulation targets, behavioral protocols, and nutritional plans.
Our collective work spans foundational molecular atlases across Alzheimer's, Huntington's, ALS, schizophrenia, and bipolar disorder, with established access to the consortia that hold the relevant data: PsychENCODE, NeuroBioBank, ENIGMA, ABCD, HCP, and UKBB. The first deployment, Neuroverse, integrates micro (single-cell and genotype), meso (brain connectomics), and macro (behavioral and wearable) scales into a single, open, FAIR-compliant architecture.
Neuropsychiatric disease is where the human cost is highest, the categorical model fails most visibly, and the noninvasive technology is most mature. It is also the proving ground for the broader platform: the same architecture, once validated in the brain, generalizes to immune, metabolic, and oncologic disease.
Building the Infrastructure of the Future
Building the core infrastructure. We are developing the Neuroverse and Immunoverse models, aggregating 10M+ cells of multi-omics data, and validating our programmable sensor technology in vitro.
From research to reality. We will launch direct-to-consumer pilots, achieve FDA clearances for autoimmune and mental health panels, and demonstrate clinical efficacy in longitudinal cohorts.
Universal access. We will deploy in emerging markets with subsidized pricing models, ensuring the geography lottery no longer dictates health outcomes.
After 37 years navigating a labyrinth of misdiagnoses, ten specialists, and failed treatments, our Founder and CEO (Shahin) did what no doctor could: he used the tools he'd spent his career building to find his own answer. One ultra-rare mutation. One root cause. Everything connected.
This diagnostic journey exposed a fundamental systemic flaw: healthcare acts reactively, waiting for disease to manifest, rather than proactively preserving health. This creates three critical blindspots:
For centuries, humanity faced a false choice: pursue profit or pursue purpose. The Helix Framework reveals this dichotomy as an illusion. Just as yin and yang are complementary aspects of a unified whole, each containing the seed of the other. Profit and purpose are two strands of the same organizational DNA.
When structured correctly, profit amplifies purpose and purpose generates profit in an upward spiral of sustainable impact. The Cytognosis Foundation serves as the first comprehensive implementation, demonstrating how mission-locked organizations can attract substantial capital while maintaining unwavering commitment to global health equity.
"Capital is oxygen for moonshots. Without it, transformative ideas suffocate before reaching the patients they could save. But here's the paradox: the moment money shifts from catalyst to purpose, we fail. True innovation emerges when mission alignment is encoded in our organizational DNA, as immutable as genetic code itself. Like the double helix, profit and purpose spiral upward together; neither can exist without the other, each stabilizing and propelling its complement."
Shahin Mohammadi, Founder
Want to learn more about our framework?
Read Full Article